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The recent discovery of functional lymphatic vessels lining the dural sinuses shattered the long held view of the
absence of CNS lymphatic vas culature and provided solid neuroanatomical ground for Neuroimmunology1.
Moreover, it has been shown that there is the presence of what is known as the inﬂammatory reﬂex. This is mediated
by sensory neurons and transmitted directly to immune cells such as the macro phages and T-cells via specialized
cholinergic receptors2. These ﬁndings demonstrate a strong interaction between the nervous and immune systems.
One of the major proteins that contribute to the pathogenesis of Parkinson's disease (PD) is alpha-synuclein (aSyn).
Surprisingly, alpha-synuclein pathogenic inclusions were recently shown spread to the brain from the gastro
intestinal tract (GIT) in a manner similar to prion diseases3. With the vagus nerve tracking through the GIT, it plays a
key role in the interaction of the brain with the immune system. Inﬂammation in the GIT leads to over expression and
aggregation of aSyn in the enteric nervous system and spreads to the vagal dorsal motor nucleus in the brainstem
via the nerve4. GIT micro bio me has been shown to be a key component of this spread by release of mediators
affecting inﬂammation3.The prion-like mechanism of spread has previously been demonstrated for ALS as well5,
where mutant SOD1 converts normal mitochondrial SOD1 into an abnormal protein leading to mitochondrial
aggregations and dys function5.
In the brain, the astrocytes maintain the blood-brain-barried (BBB) while the micro glia directly contribute to immune
defense mechanisms. Alzheimer's disease (AD) is characterized by plaques and neuro ﬁbrillary tangles (NFT), the
latter being composed predominantly of the misfolded protein Tau. In a mouse model it was shown that antibodies
directed against Tau prevented the spread of NFTs. Modulation of the Fc portion of the antibodies led to absence of
binding to micro glia with consequent reduction of release of inﬂammatory mediators and ensuing
neuroinﬂammation6. Thus such a strategy could have immune-therapeutic effects on AD.
Multiple sclerosis (MS) has seen rapid immun other apeutic advances with the advent of monoclonal antibodies.
Nataluzimab (an integrin inhibitor preventing lymphocyte extra vasation) and Rituximab (B-cell inhibitor) showed
remarkable success in disease management. Recently Ocrelizumab, a humanized form of Rituximab, was recently
approved by FDA for treatment of Primary progressive MS7. Teriﬂunamide, a hepatic metabolite of an old antirheumatic drug - Leﬂunomide, was also approved by FDA for MS8. In resource limited countries such as Pakistan,
Leﬂunomide has been successfully used for treatment of MS, though formal studies to assess its efﬁcacy are
currently lacking.
Several neuropsychiatric syndromes and immune encephalitis are now yielding to the power of Neuroimmunology
and being routinely diagnosed to be mediated by antibodies such as the anit-GABA, anti-NMDA, anti-VGKC
(CASPR2& LGI1) and the more familiar dsDNA. This has opened doors to treatments which were previously
impossible. Now chemical or biological immunomodulators are helping to bring such vague diseases under
excellent clinical control. Furthermore the recent introduction of onco-neural antibodies is an added tool in the
diagnosis of previously elusive paraneoplastic neurological syndromes.
These pathobiologic advances, combined with immunotherapeutics and a broad range of available antibody tests
has made Neuroimmunology a major diagnostic and therapeutic ﬁeld of immense clinical signiﬁcance.
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